Adel, Inc.

Private

SeoulHealthcare & Life Scienceshttps://adelpharm.com/

Last Round

Private Equity

Apr 9, 2026

Est. Valuation

$277.5M

Total Funding Raised

$56.02M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Adel, Inc. is a biopharmaceutical company that develops therapeutic antibodies and diagnostic systems for neurodegenerative diseases, with a primary focus on Alzheimer's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

Alzheimer's treatmentmonoclonal antibodymAbtau protein targetingneurodegenerative diseasedrug licensingdrug discoverydisease-modifying treatmentimmunotherapyclinical stage biotechbiopharmaADTAC platformbrain targetingautophagy targetingsmall moleculetau-based diagnosticApoE4 targeting

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adel, Inc. Comps

Public and private peers based on sector, stage, and business model.

Adel, Inc. comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Adel, Inc. Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Private Equity	Apr 9, 2026
Series B Extension	Jul 31, 2024
Series B	Oct 1, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Youngsoo Sohn

COO

Executive Team

Adel, Inc. Investors

Notable investors and investment history

Adel, Inc. investors
Investor	Rounds
Smilegate Investment	Series B Extension, Private Equity
Korea Investment Partners	Private Equity
Samsung Securities	Private Equity
Mirae Asset Securities	Private Equity
DS Asset Management	Private Equity
Timefolio Asset Management	Private Equity
Samsung Venture Investment	Private Equity

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 27, 2026
Grew 50% QoQ, from 6 to 9 employees.
Apr 12, 2026
Grew 80% QoQ from 5 to 9 employees.

View all signals

Adel, Inc. Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Adel, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Adel, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSeoul

Employee Range9

Year Founded2016

Last FundingApr 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.